This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted amino-azepines, according to Formula I or pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein: R.sup.1 is aryl optionally substituted with CN, NO.sub.2, halogen or H; R.sup.2 is H, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl, or C.sub.3-C.sub.7 heterocycloalkyl; R.sup.3 is H, OH, O--C.sub.1-C.sub.6 alkyl, SH, S--C.sub.1-C.sub.6 alkyl, or F; R.sup.4 is H, C.sub.1-C.sub.6 alkyl R.sup.5 is iso-butyl, cyclohexylmethyl, or cyclopentylmethyl; and R.sup.6 is aryl, heteroaryl.